english English    english 中文

Win-Win Fine Chemical Expert WINWIN Chemicals

On August 2, 2022, Hengrui Medicine issued an announcement that the company received the approval and issuance of the "Drug Clinical Trial Approval Notice" by the State Food and Drug Administration for HRS-4642 injection. HRS-4642 targets the KRAS G12D mutation and inhibits tumor cell proliferation. At present, no similar drugs have entered the clinic at home and abroad, and there is no relevant sales data. Therefore, Hengrui Medicine HRS-4642 is the first KRAS G12D inhibitor approved for clinical use in China. According to the statistics of Yaorong Cloud database, Hengrui Medicine HRS-4642 injection was undertaken by the Drug Application Center on May 20 this year, and it took 67 days to get the clinical approval.
Winwin Cheimcal news